Cervarix, Gardasil Set For FDA Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
You may also be interested in...
Merck Vaccine President Slot Opens Up With McGlynn's Retirement
A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.
Glaxo Boasts Its Cervarix Vaccine Protects Against Five Most Common HPV Strains
The drug maker hopes the data will reverse a long-delayed approval in the U.S., where Merck's Gardasil has a commanding lead.
Sticking Point: Cervarix Outshines Gardasil, But Practical Value Is Unclear
Merck says immune response trial provides "no clinically relevant information."